Edition:
India

Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

193.06USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$193.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
121,393
52-wk High
$200.28
52-wk Low
$103.55

Chart for

About

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops,... (more)

Overall

Beta: 0.21
Market Cap(Mil.): $7,712.59
Shares Outstanding(Mil.): 44.10
Dividend: --
Yield (%): --

Financials

BRIEF-Abiomed Q2 earnings per share $0.54

* Abiomed announces Q2 fy 2018 revenue of $132.8 million, up 29% and record u.s. Patient utilization, up 33 pct

26 Oct 2017

Abiomed invests in Israeli medical device maker Magenta

JERUSALEM Israeli medical device company Magenta Medical said on Thursday it has raised $15 million in funding led by Massachusetts-based Abiomed Inc, a maker of catheter-based heart pumps, and venture capital firm Pitango.

28 Sep 2017

Abiomed invests in Israeli medical device maker Magenta

JERUSALEM, Sept 28 Israeli medical device company Magenta Medical said on Thursday it has raised $15 million in funding led by Massachusetts-based Abiomed Inc , a maker of catheter-based heart pumps, and venture capital firm Pitango.

28 Sep 2017

BRIEF-Abiomed receives FDA PMA approval for Impella RP for right heart failure

* Abiomed receives FDA PMA approval for Impella RP for right heart failure Source text for Eikon: Further company coverage:

21 Sep 2017

BRIEF-Abiomed maintains fiscal year 2018 revenue guidance

* Says ‍is maintaining its fiscal year 2018 revenue guidance of $560 million to $575 million - SEC filing​

29 Aug 2017

BRIEF-ABIOMED says CFO Michael Tomsicek resigns

* ABIOMED announces resignation of chief financial officer and welcomes back former chief financial officer as consultant

29 Aug 2017

BRIEF-Abiomed Q1 gaap earnings per share $0.82

* Abiomed announces Q1 FY 2018 revenue of $132.5 million, up 29% over prior year

27 Jul 2017

BRIEF-Abiomed reports Q1 EPS $0.82

* Abiomed announces Q1 FY 2018 revenue of $132.5 million, up 29 pct over prior year

27 Jul 2017

BRIEF-New study with Abiomed's Impella 2.5 Heart Pump demonstrates potential survival with pre-PCI insertion in heart attacks with the left main coronary artery

* New study with Abiomed's Impella 2.5® heart pump demonstrates potential survival with pre-PCI insertion in heart attacks with the left main coronary artery Source text for Eikon: Further company coverage:

30 Jun 2017

Earnings vs. Estimates